Trial Profile
The Effect of Replacement of Vitamin K Antagonist by Rivaroxaban With or Without Vitamin K2 Supplementation on Vascular Calcifications in Chronic Hemodialysis Patients: A Randomized Controlled Trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Vitamin K2 (Primary)
- Indications Coronary artery disease; Vascular calcification
- Focus Therapeutic Use
- Acronyms The Valkyrie Study
- 25 Jan 2019 Status changed from recruiting to completed.
- 24 Nov 2015 New trial record